Similar Articles
801 Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma
802 Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management
803 Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort
804 Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma
805 CMA down-regulates p53 expression through degradation of HMGB1 protein to inhibit irradiation-triggered apoptosis in hepatocellular carcinoma
806 Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients
807 Case of hepatocellular carcinoma in a patient with hereditary tyrosinemia in the post-newborn screening era
808 Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy
809 Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2
810 Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA